Alerts will be sent to your verified email
Verify Email
BLISSGVS
|
Bliss GVS Pharma
|
Beta Drugs
|
Syncom Formulations
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
R&D as a % of Total Sales
|
2.7 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
6.83 % | 21.73 % | 9.79 % |
|
5yr average Equity Multiplier
|
1.3 | 1.75 | 1.41 |
|
5yr Average Asset Turnover Ratio
|
0.62 | 1.04 | 0.81 |
|
5yr Avg Net Profit Margin
|
8.7 % | 11.97 % | 8.78 % |
|
Price to Book
|
1.53 | 0.0 | 4.07 |
|
P/E
|
15.76 | 39.34 | 24.42 |
|
5yr Avg Cash Conversion Cycle
|
186.56 Days | 15.7 Days | 61.57 Days |
|
Inventory Days
|
54.35 Days | 43.83 Days | 27.32 Days |
|
Days Receivable
|
189.93 Days | 87.61 Days | 82.75 Days |
|
Days Payable
|
75.78 Days | 113.94 Days | 79.41 Days |
|
5yr Average Interest Coverage Ratio
|
14.68 | 13.71 | 31.44 |
|
5yr Avg ROCE
|
13.27 % | 27.85 % | 13.63 % |
|
5yr Avg Operating Profit Margin
|
17.03 % | 21.58 % | 9.97 % |
|
5 yr average Debt to Equity
|
0.11 | 0.23 | 0.19 |
|
5yr CAGR Net Profit
|
4.24 % | 31.07 % | 36.24 % |
|
5yr Average Return on Assets
|
5.31 % | 12.53 % | 7.11 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
35.39 % | 66.73 % | 50.57 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.84 % | 0.02 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Bliss GVS Pharma
|
Beta Drugs
|
Syncom Formulations
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|